Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06275893 · ClinicalTrials.gov registry record · Phase 1
IC14 (Atibuclimab) in Arrhythmogenic Cardiomyopathy
A Phase 1 study, sponsored by Implicit Bioscience.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT06275893 is a Phase 1 study that has completed, run by Implicit Bioscience. The registered enrollment target is 1 participants.
The verdict
NCT06275893, a Phase 1 study, has completed, sponsored by Implicit Bioscience.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to test IC14 (atibuclimab) in patients with arrhythmogenic cardiomyopathy (ACM) and who have an implantable cardoverter/defibrillator in place. ACM is also called arrhythmogenic right ventricular dysplasia (ARV) or arrhythmogenic right ventricular cardiomyopathy (ARVC). The main questions the study aims to answer are the effect of treatment on blood markers of inflammation, safety, and pharmacokinetics. There will also be measurements of myocardial imaging of C-C chemokine receptor type 2 (CCR2+) immune cells (optional), monitoring of cardiac arrhythmias using the patient's pre-existing intracardiac cardioverter/defibrillator (ICD) and a Holter monitor, electrocardiogram (ECG), echocardiogram (ECHO), and blood tests. Results will be compared to baseline; there is no inactive placebo treatment group. Participants will be asked to undergo screening and baseline testing, then receive 4 intravenous infusions with blood measurements before and after the infusion (including 24, 48, and 72 hours and 7, 14, and 28 days). Participants will be offered specialized scanning of the heart muscle, and will be asked to provide recordings from their ICD, undergo Holter monitoring twice, and have electrocardiograms (ECG), echocardiograms (ECHO) and blood tests.
Interventions
- BIOLOGICAL IC14
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2024-03-29 |
| Est. Completion | 2026-04-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06275893
The ClinicalTrials.gov registry entry for NCT06275893 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Implicit Bioscience, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IC14 is the first listed.
NCT06275893 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06275893 about?
NCT06275893 is a clinical study titled "IC14 (Atibuclimab) in Arrhythmogenic Cardiomyopathy". The goal of this clinical trial is to test IC14 (atibuclimab) in patients with arrhythmogenic cardiomyopathy (ACM) and who have an implantable cardoverter/defibrillator in place. ACM is also called arrhythmogenic right ventricular dysplasia (ARV) or arrhythmogenic right ventricular cardiomyopathy (A...
What is the current status of trial NCT06275893?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2024-03-29. Estimated completion is 2026-04-15.
What interventions are being tested in trial NCT06275893?
The interventions under investigation include: IC14 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06275893?
This trial is sponsored by Implicit Bioscience, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.